Targeting the RhoA pathway inhibitors may be helpful for patients with IPF, as AKAP13 interacts with both protein kinase A and the Rho/Rac family of guanosine triphosphate binding proteins [37]. Here, AKT1 is linked to idiopathic pulmonary fibrosis.